Cargando…
Rivaroxaban in atrial fibrillation cardioversion: an update
Currently, atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a prevalence of about 2–3% in the general population, representing a powerful risk factor for stroke and systemic thromboembolism and increased mortality and morbidity. Restoration of sinus rhythm is an importa...
Autores principales: | Lavalle, Carlo, Straito, Martina, Caroli, Annalisa, Piro, Agostino, Giunta, Giuseppe, Mariani, Marco Valerio, Fedele, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504667/ https://www.ncbi.nlm.nih.gov/pubmed/31118649 http://dx.doi.org/10.2147/TCRM.S201162 |
Ejemplares similares
-
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
por: Mariani, Marco Valerio, et al.
Publicado: (2020) -
Triggers for Atrial Fibrillation: The Role of Anxiety
por: Severino, Paolo, et al.
Publicado: (2019) -
Incidence and Determinants of Spontaneous Cardioversion of Early Onset Symptomatic Atrial Fibrillation
por: Mariani, Marco Valerio, et al.
Publicado: (2022) -
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
por: Jacobs, Maartje S., et al.
Publicado: (2017) -
Left Atrial Appendage Thrombosis During Therapy with Rivaroxaban in Elective Cardioversion for Permanent Atrial Fibrillation
por: Serra, Walter, et al.
Publicado: (2015)